VJHemOnc is committed to improving our service to you

VJVirtual | Azintuxizumab vedotin for R/R multiple myeloma

VJHemOnc is committed to improving our service to you

Ravi Vij

Ravi Vij, MD, MBA, Washington University Medical School, St Louis, MO, talks on the antibody-drug conjugate azintuxizumab vedotin (ABBV-838) that targets SLAMF7/CS1 in the treatment of patients with relapsed and refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter